{"commentary":{"count":37,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":16,"podcast":11,"x_thread":10},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06319820\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"MoonRISe-1","nct_id":"NCT06319820","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=moonrise-1-nct06319820. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"MoonRISe-1","arms":[{"description":"Participants in Group A will have TAR-210 inserted in the bladder on Day 1 and removed after 12 weeks. One TAR-210 will be inserted every 12 weeks over a treatment period of approximately 1 year.","label":"Main Study: Group A: TAR-210","type":"EXPERIMENTAL"},{"description":"Participants in Group B will receive intravesical mitomycin C (MMC) or gemcitabine (investigator's choice) once weekly for 4 to 6 induction doses followed by a maintenance phase for a minimum of 6 months and up to 1 year.","label":"Main Study: Group B: MMC or Gemcitabine","type":"ACTIVE_COMPARATOR"},{"description":"Participants in Group A will have TAR-210 inserted in the bladder on Day 1 and removed after 12 weeks. One TAR-210 will be inserted every 12 weeks over a treatment period of approximately 1 year.","label":"Substudy: Group A: TAR-210","type":"EXPERIMENTAL"},{"description":"Participants in substudy Group B will receive intravesical MMC once weekly for 4 to 6 induction doses followed by a maintenance phase for a minimum of 6 months and up to 1 year.","label":"Substudy: Group B: MMC","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2032-12-31","type":"ESTIMATED"},"conditions":["Non-Muscle Invasive Bladder Neoplasms"],"enrollment":{"count":641,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"TAR-210","type":"COMBINATION_PRODUCT"},{"name":"Gemcitabine","type":"DRUG"},{"name":"MMC","type":"DRUG"}],"last_update":"2026-09-25","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-06-28","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease Free Survival (DFS)","timeFrame":"From randomization to the date of the first documented recurrence, disease progression or death (approximately 4 years and 2 months)"}],"references":[],"start_date":{"date":"2024-04-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer","url":"https://clinicaltrials.gov/study/NCT06319820"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/moonrise-1-nct06319820"}